RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma.
暂无分享,去创建一个
Sopit Wongkham | S. Wongkham | S. Chariyalertsak | S. Petmitr | Ubol Chuensumran | Songsak Petmitr | Pensri Saelee | Sunanta Chariyalertsak | P. Saelee | U. Chuensumran
[1] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[2] Diane D. Liu,et al. Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[3] Y. Shim,et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. , 2003, Cancer research.
[4] Y. Wang,et al. Loss of heterozygosity on chromosome 10q22-10q23 and 22q11.2-22q12.1 and p53 gene in primary hepatocellular carcinoma. , 2004, World journal of gastroenterology.
[5] J. Herman,et al. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. , 2003, The American journal of pathology.
[6] H. Edmondson,et al. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.
[7] W. Yeo,et al. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[8] M. Toyota,et al. Detection of hypermethylation of thep16INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus , 2001, Gut.
[9] M. Washington,et al. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity , 1995, Nature Genetics.
[10] M. Ozturk,et al. Smad2 and Smad4 gene mutations in hepatocellular carcinoma , 1999, Oncogene.
[11] Chun Xing Li,et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.
[12] Takafumi Yoshida,et al. SOCS1 Is a Suppressor of Liver Fibrosis and Hepatitis-induced Carcinogenesis , 2004, The Journal of experimental medicine.
[13] J. Minna,et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.
[14] C. Croce,et al. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] S. Hirohashi,et al. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. , 1994, Cancer research.
[16] M. Kew,et al. β‐catenin mutations and expression, 249serine p53 tumor suppressor gene mutation, and hepatitis B virus infection in southern African Blacks with hepatocellular carcinoma , 2005 .
[17] U. Lehmann,et al. Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.
[18] Marius Žemaitis,et al. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. , 2007, Lung cancer.
[19] J. Kwong,et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. , 2001, Cancer research.
[20] W. Yeo,et al. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] Shirley A. Miller,et al. A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.
[22] Yucai Wang,et al. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. , 2007, Lung cancer.
[23] Chien-Jen Chen,et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1–DNA adduct levels in human hepatocellular carcinoma , 2002, Molecular carcinogenesis.
[24] W. Tsai,et al. Predicting Hepatocellular Carcinoma by Detection of Aberrant Promoter Methylation in Serum DNA , 2007, Clinical Cancer Research.
[25] F. Latif,et al. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. , 2005, Cancer research.
[26] M. Uribe,et al. Hepatocellular carcinoma. An overview. , 2006, Annals of hepatology.
[27] M. Buendia,et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[28] J. Bacik,et al. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors , 2004, Molecular Cancer.
[29] W. Yeo,et al. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] H. Donninger,et al. The RASSF1A tumor suppressor , 2007, Journal of Cell Science.
[31] J. Minna,et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] G. Pfeifer,et al. Frequent hypermethylation of the RASSF1A gene in prostate cancer , 2002, Oncogene.
[33] N. Nishida,et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.
[34] A. Heim,et al. Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. , 2007, Human molecular genetics.
[35] M. Widschwendter,et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. , 2003, Cancer research.
[36] A. Jemal,et al. Global Cancer Statistics , 2011 .
[37] S. Chi,et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. , 2001, Cancer research.
[38] S. Chi,et al. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. , 2001, Cancer research.
[39] J. Minna,et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.
[40] Chien-Jen Chen,et al. Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. , 2005, Cancer letters.
[41] G. Pfeifer,et al. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas , 2001, International journal of cancer.
[42] R. Schulte‐Hermann,et al. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. , 2006, Journal of hepatology.
[43] X. Qian,et al. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors , 2005, Laboratory Investigation.
[44] Hyeon Joo Lee,et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. , 2003, The American journal of pathology.
[45] A. Nakao,et al. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] G. Pfeifer,et al. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. , 2002, Cancer research.